T. Rowe Price Associates’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-295,741
| Closed | -$30.2M | – | 2921 |
|
|
2023
Q2 | $30.2M | Sell |
295,741
-1,324
| -0.4% | -$135K | ﹤0.01% | 830 |
|
|
2023
Q1 | $27M | Buy |
297,065
+277,696
| +1,434% | +$25.2M | ﹤0.01% | 841 |
|
|
2022
Q4 | $736K | Buy |
19,369
+323
| +2% | +$12.3K | ﹤0.01% | 1943 |
|
|
2022
Q3 | $479K | Sell |
19,046
-481,724
| -96% | -$12.1M | ﹤0.01% | 2144 |
|
|
2022
Q2 | $15.2M | Sell |
500,770
-61,979
| -11% | -$1.88M | ﹤0.01% | 1235 |
|
|
2022
Q1 | $18.4M | Sell |
562,749
-403,262
| -42% | -$13.2M | ﹤0.01% | 1243 |
|
|
2021
Q4 | $25.5M | Sell |
966,011
-90,776
| -9% | -$2.39M | ﹤0.01% | 1226 |
|
|
2021
Q3 | $106M | Sell |
1,056,787
-8,287
| -0.8% | -$834K | 0.01% | 757 |
|
|
2021
Q2 | $151M | Buy |
1,065,074
+11,342
| +1% | +$1.61M | 0.01% | 647 |
|
|
2021
Q1 | $105M | Sell |
1,053,732
-67,190
| -6% | -$6.7M | 0.01% | 758 |
|
|
2020
Q4 | $139M | Buy |
1,120,922
+200,996
| +22% | +$24.8M | 0.01% | 618 |
|
|
2020
Q3 | $89.6M | Sell |
919,926
-9,396
| -1% | -$915K | 0.01% | 690 |
|
|
2020
Q2 | $145M | Sell |
929,322
-17,814
| -2% | -$2.78M | 0.02% | 541 |
|
|
2020
Q1 | $137M | Sell |
947,136
-426,048
| -31% | -$61.5M | 0.02% | 499 |
|
|
2019
Q4 | $281M | Buy |
1,373,184
+358,752
| +35% | +$73.3M | 0.04% | 411 |
|
|
2019
Q3 | $81.4M | Buy |
1,014,432
+364,041
| +56% | +$29.2M | 0.01% | 684 |
|
|
2019
Q2 | $61.4M | Buy |
650,391
+231,369
| +55% | +$21.8M | 0.01% | 807 |
|
|
2019
Q1 | $35.8M | Buy |
419,022
+21,087
| +5% | +$1.8M | 0.01% | 992 |
|
|
2018
Q4 | $22.3M | Buy |
397,935
+656
| +0.2% | +$36.8K | ﹤0.01% | 1112 |
|
|
2018
Q3 | $32.5M | Buy |
+397,279
| New | +$32.5M | ﹤0.01% | 1065 |
|